Neurophet, an artificial intelligence (AI) solution company focused on brain diseases, is making significant strides in global expansion. The company recently announced a joint research collaboration with Nanyang Technological University (NTU) in Singapore, which was recognized at the Asian Society Against Dementia (ASAD) conference.
The collaboration involves analyzing data from the Dementia Research Centre at NTU’s Lee Kong Chian School of Medicine using Neurophet AQUA, an AI-based brain MRI analysis software. This software boasts a 5-minute processing time and a high success rate, providing consistent results regardless of race, age, or gender. The research aims to validate the effectiveness of Neurophet AQUA in diagnosing and monitoring cognitive decline in Southeast Asian populations.
The study, titled “Automatic Brain Segmentation with AQUA: A Comparative Validation Study in the Southeast Asian BIOCIS Cohort,” was awarded the Young Investigator Award at the ASAD conference and will be published in an international journal. The results demonstrated that Neurophet AQUA offers significant advantages, including faster processing time and enhanced robustness, making it a valuable tool for brain disease research and clinical practice.
Neurophet’s commitment to developing solutions for brain diseases extends beyond research. The company offers a range of products, including brain PET image analysis software (Neurophet SCALE PET) and brain imaging treatment planning software (Neurophet tES/TMS LAB). Their primary objective is to improve the lives of patients suffering from brain diseases by leveraging cutting-edge AI technology.
CEO Jake Junkil Been expressed his enthusiasm about the collaboration’s potential impact in Southeast Asia, stating, “This collaboration represents an exciting opportunity to enhance our impact especially in Southeast Asia. We will do our best to ensure that our products can be actively used across the market.” This partnership signifies Neurophet’s dedication to expanding its reach and contributing to the global fight against brain diseases.
